{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066374","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.834904+00:00","generated_at":"2026-05-22T05:16:32.697814+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MindMed reports Q1 cash $245.5M; Phase 3 trials on track for 2026 topline data","bullets":["Cash and investments $245.5M at March 31, 2025; runway into 2027 and at least 12 months beyond first Phase 3 readout.","Dosed first patient in Phase 3 Emerge study of MM120 ODT for MDD; topline data expected 2H 2026.","Enrollment on track in Phase 3 Voyage and Panorama studies for GAD; topline data 1H 2026 (Voyage) and 2H 2026 (Panorama).","Amended K2 HealthVentures loan: up to $120M available, received ~$17.8M net cash, interest-only period extended through May 1, 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066374","json":"https://secwatch.observer/filing/0000950170-25-066374.json","markdown":"https://secwatch.observer/filing/0000950170-25-066374.md","text":"https://secwatch.observer/filing/0000950170-25-066374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025066374/0000950170-25-066374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025066374/mnmd-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:16:32.697814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}